Paget Disease of Bone
📧 Sign up to get email alerts when something new happens for Paget Disease of Bone.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-04-20EMA Authorised: Aclasta (zoledronic acid) — Sandoz Pharmaceuticals d.d.
The EMA authorised Sandoz's Aclasta (zoledronic acid) for osteoporosis indications, including postmenopausal osteoporosis and Paget disease …
-
FDA approval · 2026-04-15FDA Approved: ALENDRONATE SODIUM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for ALENDRONATE SODIUM submitted by Aurobindo Pharma Limited.
-
FDA approval · 2026-03-04FDA Approved: CALCITONIN SALMON — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approves Zydus Pharmaceuticals USA Inc.'s Original Application for Calcitonin Salmon, a generic version of the established drug. This ap…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Zoledronate In the Prevention of Paget's Disease: Long Term Extension
A long-term extension trial evaluating zoledronate for the prevention of Paget's disease is currently enrolling by invitation.
-
FDA approval · 2026-02-03FDA Approved: ALENDRONATE SODIUM — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved ANI Pharmaceuticals' supplemental application for alendronate sodium, updating the approved product under the ANDA.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Genetic Analysis to Predict the Development of Paget's Disease
A University of Edinburgh study uses genetic analysis to predict the development of Paget disease of bone. The trial is currently listed as …
-
FDA approval · 2025-09-26FDA Approved: CALCITONIN SALMON — Original Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal Pharmaceuticals' original application for Calcitonin Salmon (generic), marking the entry of a generic calcitonin product…
-
CLINICAL_TRIALS research · 2025-06-18Clinical Trial Update: Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)
An ongoing clinical trial characterizes Inclusion Body Myopathy with early-onset Paget disease and frontotemporal dementia (IBMPFD). The stu…
-
CLINICAL_TRIALS research · 2025-06-18Clinical Trial Update: Characterization of Familial Myopathy and Paget Disease of Bone
An ongoing clinical trial at the University of California, Irvine is characterizing familial myopathy and Paget disease of bone to better un…
-
FDA approval · 2024-12-05FDA Approved: CALCITONIN SALMON — Original Application (Fresenius Kabi USA, LLC)
FDA approved Fresenius Kabi USA, LLC's Calcitonin Salmon as an original application (ANDA 212675), enabling the marketing of this generic ca…
-
CLINICAL_TRIALS research · 2024-11-20Clinical Trial Update: Pathophysiology of Paget's Disease of Bone
A completed Johns Hopkins University study focusing on the pathophysiology of Paget disease of bone.
-
FDA approval · 2024-09-27FDA Approved: ALENDRONATE SODIUM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for ALENDRONATE SODIUM by Aurobindo Pharma Limited (generic).
-
CLINICAL_TRIALS trial_result · 2024-08-14Clinical Trial Update: A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED) [Phase 3]
Phase 3 clinical trial evaluating MK0217 for Paget's Disease of Bone has completed (status: COMPLETED).
-
FDA approval · 2024-04-11FDA Approved: CALCITONIN SALMON — Original Application (Dr. Reddy's Laboratories, Inc.)
FDA approved the original application for Calcitonin Salmon from Dr. Reddy's Laboratories, Inc., enabling the generic to enter the market.
-
FDA approval · 2024-01-08FDA Approved: RISEDRONATE SODIUM — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for risendronate sodium by Sun Pharmaceutical Industries, expanding or modifying its labeling un…
-
FDA approval · 2023-12-18FDA Approved: RISEDRONATE SODIUM — Supplemental Application (Sun Pharmaceutical Industires Inc.)
The FDA approved a supplemental application for Risedronate Sodium submitted by Sun Pharmaceutical Industries Inc.
-
FDA label_change · 2023-10-27FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Apotex Corp)
The FDA approved a supplemental application for ibandronate sodium from Apotex Corp, typically indicating a labeling modification under the …
-
FDA approval · 2023-06-07FDA Approved: RISEDRONATE SODIUM — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for risendronate sodium from Macleods Pharmaceuticals Limited.
-
FDA approval · 2023-06-06FDA Approved: ALENDRONATE SODIUM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for ALENDRONATE SODIUM from Aurobindo Pharma Limited, enabling the approved generic formulation to b…
-
FDA approval · 2023-06-05FDA Approved: ZOLEDRONIC ACID — Original Application (Meitheal Pharmaceuticals Inc.)
The FDA approved Meitheal Pharmaceuticals' original application for zoledronic acid, enabling a generic IV bisphosphonate product. This mark…
-
FDA approval · 2023-05-12FDA Approved: RISEDRONATE SODIUM — Supplemental Application (Apotex Corp.)
FDA approved Apotex Corp.'s supplemental application for risendronate sodium (a generic osteoporosis medication) under ANDA090877.
-
FDA approval · 2023-05-11FDA Approved: ALENDRONATE SODIUM — Original Application (ANI Pharmaceuticals, Inc.)
FDA approved ANI Pharmaceuticals' Original Application (ANDA) for alendronate sodium (ALENDRONATE SODIUM).
-
FDA label_change · 2023-04-28FDA Approved: RISEDRONATE SODIUM — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved Sun Pharmaceutical Industries, Inc.'s supplemental application for risedronate sodium, resulting in updated labeling. This …
-
FDA approval · 2023-01-31FDA Approved: ALENDRONATE SODIUM — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
The FDA approved a supplemental application for alendronate sodium from Amneal Pharmaceuticals of New York LLC for use as a generic product …
-
FDA approval · 2022-04-05FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Sagent Pharmaceuticals)
The FDA approved a supplemental application for Zoledronic acid submitted by Sagent Pharmaceuticals, updating regulatory labeling per the su…